Joint Research Agreement for Development of a Novel Immunotoxin

We are pleased to announce that we have entered into a joint research agreement with Tokushu Immuno Research Institute Co., Ltd. to develop a new immunotoxin-based therapeutic. This collaboration focuses on creating treatments for rituximab-resistant malignant lymphoma and other refractory diseases involving CD20-positive immune cells. The project will utilize the institute’s proprietary anti-CD20 antibody (BM-ca), originally developed as a therapeutic for malignant lymphoma, and advance its application through immunotoxin engineering.